A61L24/0042

Biodegradable bone glue

The present invention is directed to bioresorbable polymers to be used as bone and tissue adhesives. The present invention is also directed to the synthesis of bioresorbable polymeric molecules bearing adhesive moieties and the use of such compounds in methods to glue and stabilize fractured bones and damaged tissues. The present invention is also directed to the use of such compounds as adhesive sealants for applications in wound care. The present invention is also directed to the use of such compounds as biodegradable ink for applications in tissue engineering and 3D printing. The present invention also relates to the use of such compounds as drug delivery platforms.

Adhesive devices and uses thereof

The invention features adhesive devices for holding objects (e.g., bone fragments) fixed with respect to each other.

CATECHOL BASED HOT-MELT TISSUE ADHESIVE FOR HERNIA MESH REPAIR SURGERY
20230132713 · 2023-05-04 ·

There are provided herein bioadhesive compositions which include at least one catechol derivatives, such as, caffeic acid derivatives, and at least one synthetic thermoplastic polymer, wherein exposure to heat causes the bioadhesive composition to transform into a non-solid state and to cohesively adhere to a biological tissue upon subsequent cooling. Further provided are methods of making the compositions and uses thereof in repairing tissue damage, such as, for example, in hernia repair surgeries.

Dimensionally stable molded bone replacement element with residual hydraulic activity
09849211 · 2017-12-26 · ·

The invention relates to dimensionally stable molded bone replacement elements made of mineral bone cement with residual hydraulic activity that contain at least one share of hardened mineral bone cement and at least one share of unconverted or unhardened reactive mineral bone cement, wherein the share of hardened mineral bone cement is 5% to 90% by weight. The dimensionally stable molded bone replacement elements have at least 5% of the maximum value of the strength of a completely hardened bone cement comprised of the same mineral components and with the same structural characteristics and reach compressive strengths in the range of 2 to 200 MPa. They are substantially free of water and can be converted under biological conditions.

POLYMER PARTICLES
20230190991 · 2023-06-22 ·

Described are polymers and methods of forming and using same.

Two-paste cement-forming compositions
11260144 · 2022-03-01 · ·

Injectable, ready-to-use two-paste cement-forming compositions comprise a first paste and a second paste. The first paste comprises a non-aqueous oil-based suspension of monocalcium phosphate monohydrate (MCPM) powder, at least one surfactant effective to improve compatibility of the oil and the MCPM, and an organic acid, with an oil to MCMP powder weight ratio of about 0.2 to about 0.5. The second paste comprises an aqueous suspension of β-tricalcium phosphate (β-TCP) powder and a gel-forming polymer, with a water to β-TCP powder weight ratio of about 0.3 to about 0.5. The molar ratio of β-TCP powder to MCPM powder is greater than 1. An article of manufacture comprises a first compartment in which the first paste is contained, and a second compartment in which the second paste is contained. The compositions are useful for bone repair or replacement.

Methods and Compositions For The Treatment of Degenerate Bone
20170312385 · 2017-11-02 ·

The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (“OA”), rheumatoid arthritis, and avascular necrosis.

METHOD OF TREATING A DISEASE USING A GLYCOLYTIC DEPENDENT COMPOUND

Provided are implants and a glycolytic dependent compound for use in enhancing toxicity of the glycolytic dependent compound towards a cell, tissue and/or organ e.g., a diseased cell, tissue and/or organ, wherein the implant and the glycolytic dependent compound are contacted with the cell, tissue and/or organ in a non-blended form.

Scaffolds for implanting absorbable hemostats in field conditions
11254061 · 2022-02-22 · ·

The present invention relates generally to agents and devices for promoting hemostasis and, more particularly, to bioresorbable hemostatic pads or patches releasably supported on non-resorbable scaffolds for ease of delivery in the field. A sealant and/or hemostat delivery device comprises a resorbable hemostatic pad having a wound facing side and an opposite back side, with a hemostatic and/or wound sealing agent disposed on the wound facing side; a non-resorbable scaffold having an attachment zone on said scaffold; wherein said hemostatic pad is releasably attached with the back side to the attachment zone. The bond between the scaffold and the resorbable hemostatic pad or wound dressing is either (i) severed prior to removal of the scaffold or (ii) is weakened due to the adhesive bonding them together being moisture-deactivated, or (iii) is released by mechanical disentanglement.

OSTEOGENIC BIOMATERIAL
20170291932 · 2017-10-12 ·

A composition for enhancing bone tissue repair or regeneration is described. The composition includes osteoactivin or an active peptide fragment thereof and a biocompatible material. Osteogenic orthopedic devices including the osteoactivin-containing composition are also described. The devices and compositions can be used in methods for enhancing bone tissue repair or regeneration by contacting a site in need of bone repair or regeneration in a subject with the osteoactivin-containing composition.